Retour
CervoMed Inc (CRVO) Gagner
Graphique du cours de l'action CRVO
CRVO Gagner
CervoMed Inc
$4.14
3.49%
$0.13
À la fermeture : Apr 02, 16:00:00 GMT-4
$4.14
0%
$0
Post-Marché: Apr 02, 20:00:00 GMT-4
Statistiques clés
Clôture préc.
$4
Prix d'ouverture
$3.93
Plage de la journée
$3.91 - $4.41
Plage de 52 semaines
$3.51 - $13.47
Volume
72.2K
Volume moyen
85.3K
Rendement en dividend
--
BPA (TTM)
-2.87
Capitalisation boursière
$38.2M
Qu’est-ce que CRVO ?
CervoMed, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2016-11-09. The firm is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. The company focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.